Amgen sees no bone safety concerns around experimental obesity drug
Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone mineral density, a day after data from an early-stage study dragged its stock 7% lower.
Amgen sinks as Cantor flags issues with obesity drug
Olivia Brayer, Cantor Fitzgerald, joins 'Fast Money' to discuss Amgen shares sliding on bone density data. Cowboys 9x All-Pro predicted to cut ties with Dallas, join Bears Florida’s Retirees Are Fleeing: Experts Predict These 5 States Will Be Top Retirement Spots in 10 Years The most influential female singers of the last decade I ditched my car and hopped on a train to the Grand Canyon.
Amgen rebounds after denying bone safety concerns linked to obesity drug
Amgen (NASDAQ:AMGN) shares spiked in the premarket on Wednesday after the company ruled out concerns over loss of bone mineral density linked to its obesity candidate MariTide, which led to a ~7% decline in its share price in the previous session.
Amgen dismisses bone density concerns related to its weight-loss drug
Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a day after those concerns wiped off more than $12 billion from the company's market value.
Amgen stock falls as analysts mull over weight loss drug’s bone density data
Analysts cited data from a phase one study showing the highest dose of Amgen's MariTide was linked to roughly 4% loss of bone mineral density over 12 weeks.
Hosted on MSN1d
Novo Stock Has Been Slammed. How a New Weight-Loss Drug Could Boost Shares by 10%.
Novo Nordisk is working on a new obesity drug that could help patients shed more than any other weight-loss drug on the ...
Novo’s New Obesity Drug Is Targeting the Most Dramatic Weight Loss Yet
The drugmaker hopes to show CagriSema leads to at least 25% weight loss, without increased side effects. Its lead in a ...
Obesity Drug Shows Promise in Easing Knee Osteoarthritis Pain
A large trial showed that semaglutide, sold as Ozempic for diabetes and as Wegovy for obesity, was better than any current ...
New study suggests weight loss drugs like Ozempic could help with knee pain. Here’s why there may be a link
A recent study found semaglutide – the drug known as Ozempic – can improve knee pain in people with obesity and ...
STAT1h
BioNTech acquires its Chinese cancer drug partner
BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two ...
BioPharma Dive12d
Novo, with new results, to seek approval for obesity drug in MASH
The Phase 3 findings position semaglutide to become the first drug of its kind for the liver disease. But they also confirm ...
Novo Nordisk expects high demand for its obesity drugs in India, says country head
Popular weight-loss drug Wegovy maker Novo Nordisk expects high demand and acceptance for its anti-obesity drug, when ...
MedPage Today on MSN1d
ObesityWeek Roundup: Patients More Likely to Ration Weight-Loss Drugs
SAN ANTONIO -- Research presented at the ObesityWeek annual meeting included studies on rationing of prescription medications ...
Can new weight loss drugs fight the US obesity epidemic? Here's what to know
Obesity caused by a lifestyle of moving less and eating more is a prime factor contributing to Type 2 diabetes. Is the answer new weight loss drugs?
Weight-loss drugs can help stroke survivors prevent recurrence
The weight-loss drug Ozempic can help reduce stroke patients' risk of a heart attack or death, a new study says.
New rare disease drugs firm Oranda seeks to raise up to €35m
A new Dublin-headquartered company for rare diseases, Oranda Therapeutics, is seeking to raise €35 million in an early-stage ...